BEBPA US Bioassay

BEBPA US Bioassay

Improving hospital performance with real-time analytics: a Labcorp and Ochsner Health case study

How Labcorp's Visiun analytics platform helped Ochsner Health improve efficiency, reduce costs and enhance patient outcomes. 

How investigational new drug studies completed at China site led to expedited regulatory approval for sponsor's orphan drug

Navigating complexities in ADC development with specialized global laboratory support and scientific expertise

Anti-Drug Antibody (ADA) positive controls generation against oligonucleotide therapeutics: Anti-Oligonucleotide antibody case study

Oligonucleotide therapeutics are generally single-stranded synthetic oligonucleotides with modifications in their structure to improve stability and PK properties. These therapeutics generally target RNA transcripts and reduce or modify the corresponding protein expression. Unlike most typical biologic drug classes such as monoclonal antibodies, the oligonucleotides are relatively small in size and contain fewer potential epitopes. In addition, the oligonucleotide therapeutics are delivered to immune restricted sites to remain locally confined.

Molecular Tumor Board: 48 year-old female with cutaneous melanoma harboring NRAS Q61R mutation

Molecular Tumor Board: 69-year-old male with metastatic urothelial carcinoma with FGFR3 mutation

Supporting diabetes education and prevention in the state of Virginia: A partnership with the Virginia Department of Health

In a partnership between Labcorp and the Virginia Department of Health (VDH) to enroll patients with prediabetes in the evidence-based, CDC-backed National Diabetes Prevention Program (NDPP), Labcorp leveraged its robust lab data to email NDPP education and enrollment information to 156K Virginians meeting this criterion. As a result of the program, the VDH saw a 20-fold increase in enrollment in the NDPP.

How two Labcorp physicians are training the next generation of pathologists

Pathologists play a major role in healthcare, but not everyone knows just how big a part they really play. That’s because pathologists often operate behind the scenes, providing diagnoses on a wide variety of tissue samples and performing clinical interpretation of laboratory results. They can also hold key leadership roles in laboratory quality systems and laboratory regulations. To put it simply, their work is vital to diagnosing, treating and curing disease.However, the number of pathologists in the U.S. decreased by almost 18% between 2007 and 2017, according to a National Institutes of Health survey. At the same time, the workload per pathologist increased by almost 42%. Dr. Brian Poirier, medical director of coagulation and endocrinology laboratories at Labcorp Esoteric Business Unit (EBU) Labs, and Dr. Deborah Sesok-Pizzini, chief medical officer at Labcorp Diagnostics, knew something had to be done.

Lab stewardship program reduces unnecessary costs and improves patient care

A large, Chicago-based FQHC network wanted to optimize efficiency of testing, improve patient care and provide better, more accurate testing for their highrisk population, while also eliminating unnecessary testing expenses. The network, however, faced a lack of population health analytics tools and limited funding to invest in developing their own.